Prothena (PRTA) Expected to Announce Quarterly Earnings on Thursday

by · The Cerbat Gem

Prothena (NASDAQ:PRTA – Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Prothena to announce earnings of ($0.2271) per share and revenue of $9.58 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. The firm had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.42 million. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%. On average, analysts expect Prothena to post $0.08 EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Prothena Stock Up 1.2%

Shares of NASDAQ PRTA traded up $0.10 during trading hours on Tuesday, hitting $8.39. The company had a trading volume of 23,997 shares, compared to its average volume of 509,405. The stock has a market capitalization of $439.06 million, a P/E ratio of -10.00, a price-to-earnings-growth ratio of 3.21 and a beta of -0.29. Prothena has a 1-year low of $7.73 and a 1-year high of $11.80. The firm’s 50 day moving average is $8.74 and its 200-day moving average is $9.22.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on PRTA shares. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Prothena in a report on Friday, July 24th. Weiss Ratings cut shares of Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen downgraded shares of Prothena from a “buy” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, UBS Group reiterated a “buy” rating on shares of Prothena in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Get Our Latest Report on Prothena

Insider Buying and Selling

In related news, major shareholder William P. Scully purchased 162,000 shares of the stock in a transaction on Tuesday, September 29th. The shares were purchased at an average cost of $8.68 per share, with a total value of $1,406,160.00. Following the acquisition, the insider directly owned 214,000 shares in the company, valued at $1,857,520. The trade was a 311.54% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have bought 1,017,500 shares of company stock valued at $8,654,850. 10.40% of the stock is currently owned by corporate insiders.

Prothena Company Profile

(Get Free Report)

Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel medicines for serious neurodegenerative and rare peripheral diseases. Its research is centered on disease-causing proteins, including amyloid-beta, alpha-synuclein and transthyretin, with the goal of creating antibody-based therapies that address underlying disease mechanisms.

The company’s product pipeline has included birtamimab, an investigational antibody being developed for the treatment of AL amyloidosis, and prasinezumab, an investigational alpha-synuclein antibody being developed in collaboration with Roche for certain forms of Parkinson’s disease.

Featured Articles